Spring Bank Pharmaceuticals Announces Clinical Trial Collaboration with Gilead Sciences for Hepatitis B (HBV) Phase 2 Clinical Trial

19 Nov, 2015, 08:00 ET from Spring Bank Pharmaceuticals, Inc.

MILFORD, Mass., Nov. 19, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced a clinical trial collaboration with Gilead Sciences for a Hepatitis B (HBV) Phase 2 clinical study with Spring Bank's SB 9200 in combination with Viread® (tenofovir disoproxil fumarate) for HBV patients.

Dr. Nezam Afdhal, Spring Bank's Chief Medical Officer, said "Although medications like Viread® are excellent at suppressing HBV replication, 'HBV cure' has remained elusive. We are very excited to move SB 9200 into Phase 2 clinical development in collaboration with Gilead.  We believe that SB 9200 has the potential to be an important advance in the treatment of HBV patients, providing the potential for clearance of HBsAg, or functional cure, and will be studied both alone and in combination with Viread®."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of orally bioavailable therapeutics based on its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins or enzymes implicated in various disease states. The Company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. SB 9200 has been designed to selectively activate the host cellular proteins, RIG I and NOD 2, which have been implicated in the body's immune response to viral infections. Spring Bank believes that SB 9200 can play an important role in antiviral therapy by modulating host immune response to fight viral infections such as HBV, HCV and RSV.

Contact:
Maeve Conneighton
Argot Partners
(212) 600-1902
maeve@argotpartners.com

SOURCE Spring Bank Pharmaceuticals, Inc.



RELATED LINKS

http://www.springbankpharm.com